
Listing of Claims:

The following listing of claims replaces all prior versions and listings of claims in the application:

- 1-87. (Canceled)
88. (Previously Presented) A polypeptide having the sequence SEQ ID NO:56.
89. (Previously Presented) The polypeptide of claim 88, which is glycosylated.
90. (Previously Presented) The polypeptide of claim 89, further comprising at least one PEG molecule covalently attached to the polypeptide.
91. (Previously Presented) The polypeptide of claim 90, comprising one PEG molecule covalently attached to the polypeptide.
92. (Previously Presented) The polypeptide of claim 91, wherein the PEG molecule has a molecular weight of about 12 kDa.
93. (Previously Presented) The polypeptide of claim 91, wherein the PEG molecule has a molecular weight of about 20 kDa.
94. (Previously Presented) A composition comprising the polypeptide of claim 89 and a pharmaceutically acceptable diluent, carrier, or excipient.
95. (Previously Presented) A composition comprising the polypeptide of claim 93 and a pharmaceutically acceptable diluent, carrier, or excipient.
96. (Previously Presented) A nucleic acid comprising a nucleotide sequence encoding the polypeptide of claim 88.

97. (Previously Presented) An expression vector comprising the nucleic acid of claim 96.

98. (Previously Presented) A glycosylating host cell comprising the expression vector of claim 97.

99. (Previously Presented) The glycosylating host cell of claim 98, wherein the host cell is a CHO cell.

100. (Previously Presented) A method of making a polypeptide, the method comprising: providing a culture comprising a glycosylating host cell, the glycosylating host cell comprising a nucleotide sequence which encodes the polypeptide of claim 88, culturing the culture under conditions which permit expression and glycosylation of the polypeptide, and recovering the polypeptide.

101. (Previously Presented) The method of claim 100, wherein the glycosylating host cell is a CHO cell.

102. (Previously Presented) The method of claim 100, further comprising attaching at least one PEG molecule to the polypeptide.

103. (Withdrawn) A method of treating a mammal with a disease for which interferon β is a useful treatment, the method comprising administering to the mammal an effective amount of the composition of claim 95.

104. (Withdrawn) The method of claim 103, wherein the disease is multiple sclerosis.

105-121. (Canceled)